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Abstract 37 
 38 
Enzymes catalysing remarkable Diels-Alder-like [4+2] cyclisations have been 39 
previously implicated in the biosynthesis of spirotetronate and spirotetramate 40 
antibiotics. Biosynthesis of the polyether antibiotic tetronasin is not anticipated to 41 
require such steps, yet the tetronasin gene cluster encodes enzymes Tsn11 and Tsn15, 42 
homologous to authentic [4+2] cyclases. Here we show that deletion of Tsn11 led to 43 
accumulation of a late-stage intermediate, in which the two central rings of tetronasin, 44 
and four of its 12 asymmetric centres, remain unformed. In vitro reconstitution 45 
showed that Tsn11 catalyses an apparent inverse-electron-demand hetero Diels-Alder-46 
like [4+2] cyclisation of this species to an unexpected oxadecalin compound, which is 47 
then rearranged by Tsn15 to form tetronasin. To gain structural and mechanistic 48 
insight into the activity of Tsn15, a 1.7 Å crystal structure of a Tsn15-substrate 49 
complex has been solved. 50 
 51 
Introduction 52 
The Diels-Alder reaction1, in which a 1,3-diene and an alkene (dienophile) undergo a 53 
concerted [4+2] cycloaddition to form a cyclohexene ring, is of central importance to 54 
synthetic organic chemistry2. Transformations during the biosynthesis of numerous 55 
cyclic microbial metabolites have been speculated to be catalysed by naturally-56 
evolved [4+2] cyclase ("Diels-Alderase") enzymes3,4, and several enzymes have been 57 
shown to catalyse [4+2] cyclisations consistent with this mechanism5–12. Almost all 58 
examples studied so far involve the combination of an electron-rich 1,3-diene with an 59 
electron-poor dienophile to form cyclohexene-containing products. Important 60 
exceptions are the hetero-[4+2] cycloadditions catalysed by the pyridine synthases of 61 
 3
thiopeptide antibiotic biosynthesis13 and by LepI, which installs a dihydropyran 62 
during leporin B biosynthesis14 (Fig. 1a). In the case of LepI, an electron-poor 63 
(oxygen-based) diene reacts with an electron-rich dienophile in an inverse-electron-64 
demand hetero-Diels–Alder reaction14.   65 
 66 
Fig. 1 | [4+2] cyclases in polyether tetronate biosynthesis. a, Structures of pyrroindomycin and leporin B, two polyketide natural products that 67 
require a [4+2] cyclase in their biosynthesis to create the rings highlighted in red. b, Structures of the polyether tetronate antibiotics tetronasin (1) 68 
and tetronomycin. c, Proposed role of the [4+2] cyclase homologues Tsn11 and Tsn15 in tetronasin biosynthesis.  69 
 70 
Tetronasin (1) (Fig. 1b) from Streptomyces longisporoflavus, which has found use as 71 
an antibiotic and antiparasitic agent, is an unusual polyether ionophore containing an 72 
acyltetronic acid moiety15. It bears a near mirror-image structural relationship to 73 
tetronomycin (tmn) from Streptomyces sp. NRRL 1126616, whose biosynthesis has 74 
been shown to involve assembly of the polyketide backbone on a modular polyketide 75 
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synthase (PKS)16, with release of the chain via tetronic acid ring formation17. 76 
Formation of the tetrahydrofuran ring occurs by epoxidation followed by ring-77 
opening and concomitant cyclisation by an epoxide hydrolase16. The origins and the 78 
timing of central cyclohexane and tetrahydropyran rings remain unknown, although a 79 
plausible metal-assisted cascade mechanism has been suggested in which both rings 80 
are formed in a single step following release of the polyketide chain from the PKS18,19.  81 
 82 
Intrigued by the biosynthetic mystery of the origin of the two central rings, herein we 83 
show that the cyclohexane and tetrahydropyran rings of tetronasin are formed in a 84 
two-step enzymatic cascade reaction. The two enzymes responsible, Tsn11 and Tsn15, 85 
are homologues of [4+2] cyclases enzymes found in complex spirotetronate/tetramate 86 
pathways. Using a tetronasin precursor isolated from a S. longisporoflavus ∆tsn11 87 
mutant (3), we show that Tsn11 catalyses an apparent inverse-electron-demand 88 
hetero-Diels-Alder reaction of this species to produce an unexpected oxadecalin 89 
intermediate (4). Tsn15 then catalyses a rearrangement that forms the tetrahydropyran 90 
ring and dismantles the oxadecalin moiety, producing tetronasin. To gain insight into 91 
the structure and mechanism of Tsn15, a 1.7 Å crystal structure of a Tsn15-substrate 92 
complex was solved. Mutagenesis experiments then indicated that, like its 93 
homologues that catalyse [4+2] cycloadditions, Tsn15 also uses a pericyclic 94 
mechanism for ring formation.   95 
  96 
 97 
 98 
 99 
 100 
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Results 101 
 102 
The PKS-bound linear intermediate of tetronasin. We have re-analysed the 103 
previously sequenced tetronasin biosynthetic gene cluster (GenBank: FJ462704) (tsn)  104 
(Supplementary Figure 1) and used domain analysis of the PKSs to predict the 105 
structure of the hypothetical full-length polyketide (Supplementary Figure 2). To 106 
investigate whether further enzymatic reactions tailor the structure before release 107 
from the PKS enzymes, we used a chemical probe (methyl 6-decanamido-2-fluoro-3-108 
oxohexanoate 620 designed to intercept PKS-bound intermediates in vivo on the tsn 109 
PKS enzymes. In doing so we detected an incomplete undecaketide polyketide chain 110 
in which tetrahydrofuran ring formation, C-25 O-methylation and hydroxylation at C-111 
30 had all apparently occurred, forming 2, the postulated PKS-bound intermediate 112 
(Fig. 1c, Supplementary Figure 3). While we cannot rule out that these enzymatic 113 
modifications occurred after being offloaded by 6, the detection of 2 strongly suggests 114 
that they occur before polyketide chain release from the PKS enzymes, as previously 115 
established for other polyethers21.  116 
 117 
 [4+2] cyclase homologues present in the tetronasin biosynthetic gene cluster. The 118 
tetronasin cluster includes a gene, tsn11, which is the homologue of tmn9 (38% 119 
identity at the protein sequence level), previously shown to be essential for 120 
tetronomycin biosynthesis16. Intriguingly, both of these gene products show 121 
significant sequence similarity to the monooxygenase-like [4+2] cyclases that catalyse 122 
dialkyldecalin formation in the biosynthetic pathways to the spirotetramate 123 
pyrroindomycin (PyrE3)11 and the spirotetronates versipelostatin (VstK)9 and 124 
chlorothricin (ChlE3)11 (42-44% protein sequence identity) (Fig. 2a, Supplementary 125 
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Figure 4). Like PyrE3, Tsn11 contains mutations in several of the four positively 126 
charged amino acids (typically arginine) involved in interacting with NADPH22,23, 127 
immediately suggesting that it is not a functional monooxygenase (Supplementary 128 
Figure 4). 129 
 130 
Fig. 2 | Functional characterisation of the Diels-Alderase homologues Tsn11 and Tsn15 in tetronasin biosynthesis. a, The biosynthetic gene 131 
clusters of tetronomycin (tmn) and tetronasin (tsn) encode a VstJ-like (red) and PyrE3-like (yellow) [4+2] cyclase characteristic of spirotetronate 132 
and spirotetramate biosynthesis pathways including abyssomicin (aby), chlorothricin (chl), veripelostatin (vst), and pyrroindomycin (pyr). Only 133 
partial biosynthetic gene clusters are displayed and individual genes are not shown to scale. b, HPLC-MS analysis of the production of tetronasin 1 134 
(m/z = 625) and intermediate 3 (m/z = 625) from wildtype S. longisporoflavus, S. longisporoflavus ∆tsn11, ∆tsn15, and ∆tsn11 ∆tsn15, gene 135 
deletion mutants, and genetically complemented S. longisporoflavus deletion mutants. Data are representative of three independent experiments. c, 136 
HPLC analysis of the in vitro conversion of intermediate 3 into tetronasin 1 using purified Tsn11 and Tsn15. Data are representative of three 137 
independent experiments. 138 
 139 
Co-located with tsn11 is a second, previously unannotated, gene tsn15 which also has 140 
a counterpart in the tmn cluster (tmn8)16. The products of the latter two genes 141 
resemble a second family of Diels-Alderase-like cyclases (VstJ, PyrI4, and AbyU) 142 
which create the spiro moiety in spirotetronates and spirotetramates9–11 (Fig. 2a, 143 
Supplementary Figure 5).   144 
 145 
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Tsn11 and Tsn15 are essential for tetronasin biosynthesis. To analyse the potential 146 
roles of Tsn15 and Tsn11 in the biosynthesis of tetronasin (which contains neither a 147 
dialkyldecalin nor a spirotetronate moiety), we specifically deleted each gene in S. 148 
longisporoflavus (Supplementary Figure 6). LC-MS analysis of fermentation extracts 149 
(Fig. 2b) showed that deletion of either gene abolished tetronasin production, and that 150 
complementation in trans using the wildtype gene restored production in both cases. 151 
In the Δtsn11 mutant a new metabolite, 3, with the same molecular weight as 152 
tetronasin 1 accumulated which was also produced by a Δtsn11 Δtsn15 double mutant 153 
(Fig. 2b, Supplementary Figure 6c), implying that Tsn11 acts before Tsn15. The new 154 
metabolite was isolated from the Δtsn11 mutant and its structure was determined 155 
using mass spectrometry and NMR spectroscopy to be 3 (Fig. 1c, Supplementary 156 
Figures 7a, 8, 9, 24-29, Supplementary Table 1, Supplementary Note 1). The new 157 
metabolite 3 differs from 1 in lacking both central six-membered rings of tetronasin, 158 
directly implicating Tsn11 and Tsn15 in catalysing ring formation as the final steps of 159 
the biosynthetic pathway. 160 
  161 
In vitro reconstitution of the cyclohexane and tetrahydropyran rings of 162 
tetronasin.  To attempt in vitro reconstitution of 1 from 3, Tsn11 and Tsn15 were 163 
individually expressed and purified from Escherichia coli (Supplementary Figure 10). 164 
Tsn11 was found to have flavin adenine dinucleotide (FAD) as a tightly bound 165 
cofactor (Supplementary Figure 10b). Incubation of 3 with Tsn11 in vitro led to its 166 
disappearance within 1 h (Fig. 2c) and HPLC-MS analysis showed the accumulation 167 
of a new compound 4. Tsn11 could not oxidise NADPH or NADH and assaying the 168 
activity of Tsn11 pre-incubated with sodium dithionite, to reduce the bound FAD, 169 
showed that change in its redox state did not inhibit the reaction of Tsn11 with 3 170 
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(Supplementary Figure 11), consistent with previous reports11,22 that bound FAD is a 171 
passive spectator in the active site of flavocyclase PyrE3 in pyrroindomycin 172 
biosynthesis. The incubation of 3 with Tsn11 was scaled up to isolate larger amounts 173 
of 4, and its structure was determined by mass spectrometry and NMR spectroscopy 174 
analysis (Fig 1c, Supplementary Figures 7b, 12, 13, 30-35, Supplementary Table 2, 175 
Supplementary Note 2). Like 3, compound 4 still lacks the tetrahydropyran ring but 176 
the cyclohexane ring has closed within an unexpected oxadecalin hemiacetal moiety. 177 
The formation of an oxadecalin intermediate by Tsn11 is strikingly reminiscent of the 178 
formation of carbocyclic decalin rings catalyzed by its [4+2] cyclase homologs 179 
(PyrE3, ChlE3) in spirotetronate/spirotetramate biosynthesis11.   180 
 181 
Conversion of 4 into 1 requires dehydration of the hemiacetal, fragmentation of the 182 
oxadecalin ring, and a bond to form between the C17-OH and C13 to form the 183 
tetrahydropyran ring. Remarkably, incubation of 4 with Tsn15 alone, or of 3 with 184 
both Tsn11 and Tsn15, led to complete conversion to 1 within 10 minutes (Fig. 2c, 185 
Supplementary Figures 13, 14), Neither the Tsn11- nor the Tsn15-catalyzed reaction 186 
proceeded in the absence of enzyme. Despite the evident similarity between the 187 
tetronasin and tetronomycin pathways, purified Tmn9 could not substitute for Tsn11 188 
in the assay, nor could purified Tmn8 substitute for Tsn15 (Supplementary Figure 16).  189 
 190 
To probe the timing of cyclohexane and tetrahydropyran formation, the Δtsn11 and 191 
Δtsn15 mutant strains of S. longisporoflavus were treated in vivo with the chemical 192 
probe 6 20.  Exactly the same partially-assembled polyketide species were observed as 193 
from wildtype cells (Supplementary Figure 3). These data are consistent with the view 194 
that tetronate and tetrahydrofuran ring formation, C30-hydroxylation, and C25-O-195 
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methylation may precede tetrahydropyran and cyclohexane formation. 3 and 4 are 196 
therefore likely true biosynthetic intermediates in vivo and the central six-membered 197 
rings of tetronasin are formed after polyketide chain release, as final steps in the 198 
pathway. Between them, these two enzymes establish the configuration at four 199 
asymmetric centres in tetronasin24.  200 
 201 
Cycloadditions of 1-oxa-1,3-butadienes via inverse-electron-demand hetero-Diels–202 
Alder reactions are important transformations in synthetic chemistry25,26, so an 203 
enzymatic counterpart like Tsn11 is of considerable interest. The formation of trans-204 
oxadecalin 4 seems consistent with such a mechanism, but a stepwise process cannot 205 
be ruled out (Supplementary Figure 17). Likewise, alternative mechanisms are 206 
possible for the reaction catalysed by Tsn15 to convert 4 into 1 (Supplementary 207 
Figure 17). A previous isotope feeding study established that the ketone oxygen atom 208 
at C3 is derived from propionate rather than water15, indicating that any mechanism in 209 
which the C3 oxygen is derived from water is unlikely (Supplementary Figure 17).  210 
 211 
The structure of Tsn15. We propose that Tsn11, like its spirotetronate/spirotetramate 212 
homologs, catalyses a [4+2] cycloaddition even though the resulting ring is latent, that 213 
is, does not appear in the final antibiotic structure. The structure and mechanism of 214 
Tsn11 is currently under investigation. To gain insight into the specificity and 215 
mechanism of the unusual transformation catalysed by Tsn15, we have solved the 216 
crystal structure of Tsn15 at 1.8 Å using SAD phasing (Fig. 3), and also that of a 217 
Tsn15-substrate 1:1 complex, obtained by co-crystallisation of Tsn15 and 4, at 1.7 Å 218 
(Fig. 5).  219 
 220 
 10
 221 
Fig 3 | Crystal structure of Tsn15. The crystal structure of Tsn15 was solved to 1.8 Å resolution using SAD phasing. a, Ribbon 222 
and surface representation of the homodimeric Tsn15. b. The active-site cavity within the β-barrel of Tsn15. Right: surface 223 
charge representation contoured at ±5 kT/eV; blue/red.  224 
  225 
Consistent with its quaternary structure in solution (Supplementary Figure 18), Tsn15 226 
crystallised as a homodimer of two antiparallel-facing monomers (Fig. 3a). Each 227 
monomer chain consists of an N-terminal α-helical dimerisation region (α1-α3) 228 
followed by an eight-strand β-barrel (β1-β8, α4) enclosing a 388 Å3 hydrophobic 229 
internal cavity (Fig. 3b, Supplementary Figure 19, 20). Each Tsn15 monomer shows 230 
the conserved domain fold previously seen in the [4+2] cyclases of spirotetronate and 231 
spirotetramate biosynthesis (PyrI4 and AbyU)10,27, despite low (ca. 20% sequence 232 
identity). In addition to these homodimeric [4+2] cyclases, Tsn15 also shares its fold 233 
with the homotrimeric allene oxide cyclase enzymes, which catalyse a 4π 234 
electrocyclisation (pericyclic) reaction in jasmonic acid biosynthesis28,29, and PodA, 235 
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an unusual pyocyanin demethylase from Mycobacterium fortuitum30. The different 236 
activities of these homologous enzymes demonstrate remarkable ability of this protein 237 
fold to catalyse a diverse range of reactions (Fig. 4).  238 
 239 
Fig. 4 | Structural homologues of Tsn15 and their respective reactions.  The Cα chain of Tsn15 was aligned with its 240 
structural homologues AbyU, PyrI4, AOC2, and PodA. Beside each structure is its rmsd value to Tsn15, amino acid identity (%) 241 
to Tsn15, and the reaction it catalyses.  242 
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 243 
There are no significant conformational differences between the Cα chains of the two 244 
crystal structures (Supplementary Figure 21). In the Tsn15-substrate co-crystal the 245 
hemiacetal C3 hydroxyl of 4 had undergone dehydration to produce 5 (Fig. 5a). The 246 
tetronate ring of 5 is fully inserted into the β-barrel cavity of Tsn15, with the 247 
tetrahydrofuran moiety protruding into the solvent (Fig. 5b). The sidechains of amino 248 
acid residues S142 and Q164 form hydrogen bonds to the tetronate of 5 (Fig. 5c) and 249 
R89 is hydrogen-bonded to the C30-OH (chain B only) (Supplementary Figure 22).  250 
 251 
 252 
Fig. 5 | Structure of Tsn15 and a Tsn15-substrate complex. a,  Fo-Fc of 5 (contoured to 2.0 σ ) and its chemical structure.  253 
b, Tsn15 in complex with intermediate 5. The Fo-F c map of 5 could be clearly assigned in the β-barrel cavity of Tsn15 chain A. 254 
Contouring to 2.0 σ. c, The detailed binding interactions between intermediate 5 and the internal β-barrel residues of Tsn15 255 
(chain A) are shown. The dotted grey lines represent hydrogen bonding. 256 
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Our initial hypothesis was that Tsn15 might use acid/base catalysis to activate the C-259 
17 hydroxyl and promote nucleophilic ring closure of the tetrahydropyran ring. 260 
However, mutagenesis of individual acidic and basic amino acid residues within the 261 
β-barrel (R89, E109, and D122) showed that none are essential for Tsn15 activity 262 
(Supplementary Figure 23). Further alanine mutagenesis highlighted W190 (essential) 263 
and Q164 (mutant shows ca. 30% wildtype activity) both of which are likely 264 
important for substrate binding and selectivity (Supplementary Figure 23). W190 265 
appears to orient the oxadecalin moiety of 5 through π-stacking interactions (an 266 
equivalent tryptophan is conserved in Tmn8, suggesting a conserved role in binding 267 
oxadecalin polyether tetronate intermediates) (Fig. 5c, Supplementary Figure 5). The 268 
12 N-terminal amino acids of Tsn15 do not form an essential substrate-enclosing lid26, 269 
as removing these residues did not abolish enzyme activity as in the case of PyrI427 270 
(Supplementary Figure 23). The inability to identify essential general acid/general 271 
base catalytic residues suggests that the active site of Tsn15 is primarily a 272 
hydrophobic pocket that promotes a reactive conformation, possibly producing the 273 
tetrahydropyran ring via a pericyclic rearrangement (Fig. 6) similar to the 274 
mechanisms proposed for its homologue AOC228 and the [4+2] cyclases PyrI427and 275 
AbyU10. One complication with this proposal is that the conformation of 5 in the 276 
active site appears to be inert for tetrahydropyran formation, with the atoms that must 277 
form a bond, C13 and the oxygen of the C17 hydroxyl, being 4.6 Å apart. A possible 278 
explanation for this could be that the conformational rigidity imposed on Tsn15 when 279 
it crystallised prevented 5 from adopting a near attack conformation. It is also notable 280 
that 5 is present in the active site of Tsn15 rather than 4 or tetronasin 1. We had 281 
thought it more likely that 4 would be converted by Tsn15 and tetronasin 1 would 282 
therefore cocrystallise in its active site, analogous to the PyrI4 cocrystallisation 283 
 14
experiments27. One explanation for this could be that 5 is an inert spontaneous 284 
dehydration product of 4, the true substrate. If 4 is the true substrate, however, then 285 
tetrahydropyran formation and dehydration at C3 must occur simultaneously 286 
(Supplementary Figure 17b), which would likely require an acidic residue to donate a 287 
proton to the hemiacetal hydroxyl, thereby creating a better leaving group. However, 288 
as demonstrated, the acidic groups in the active site are not essential and no acidic 289 
amino acid is adjacent to C3, so it is not clear how this could occur. While we cannot 290 
rule out 5 being inert, in our view 5 is more likely to be the Tsn15 substrate as the 291 
dehydration of 4 to form 5 should be a favourable first step for tetronasin formation. 292 
Dehydration of the hemiacetal hydroxyl (whether spontaneous or Tsn15 catalysed) 293 
would stabilise the anion that forms at the C3 oxygen during tetrahydropyran 294 
formation through conjugation with the C1 and C33 carbonyl groups (Supplementary 295 
Figure 17a, 17c, 17e). While the exact mechanism used by Tsn15 to convert 4 into 296 
tetronasin remains unknown, our data is more consistent with Tsn15 catalysing a 297 
pericyclic rearrangement rather than a nucleophilic acid/base reaction (Fig. 6).  298 
Regardless, the crystal structure of Tsn15 with 5 in its active site delineates the 299 
substrate-binding residues of Tsn15 and provides a robust foundation for conducting 300 
future mechanistic studies on this fascinating class of cyclase.  301 
 302 
 303 
 304 
 15
 305 
 306 
Fig. 6 | Proposed mechanism for formation of the cyclohexane and tetrahydropyran rings of tetronasin. Tsn11 catalyses an 307 
inverse-electron-demand hetero-Diels-Alder reaction to form an oxadecalin intermediate. The oxadecalin is hydrated to form the 308 
cyclic hemiacetal 4 which was purified from the Tsn11 + 3 assay and structurally characterised. Tsn15 then catalyses 309 
dehydration of 4 to form 5 (which crystallised in the active site of Tsn15), followed by a pericyclic rearrangement to form the 310 
tetrahydropyran ring and fragment the oxadecalin, producing tetronasin 1.  311 
 312 
Our results show that the standalone enzyme Tsn11 catalyses a previously 313 
unsuspected intramolecular [4+2] cycloaddition that, in formal terms, represents an 314 
inverse-electron-demand hetero-Diels-Alder reaction26 and which constitutes a latent 315 
but compelling mechanistic link with spirotetronate and spirotetramate biosynthesis. 316 
Likewise, Tsn15, structurally homologous to known Diels-Alderase-like cyclases, has 317 
evolved to catalyze a different, but possibly also a pericyclic, transformation. From a 318 
synthetic biology perspective, these enzymes could be useful for stereospecifically 319 
synthesising cyclohexane and tetrahydropyran moieties in synthetic polyether 320 
ionophore analogues. The tolerance of Tsn15 to mutations in its active site and the 321 
diverse range of reactions catalysed by its protein fold (Fig. 4) further suggests it may 322 
have some potential as a biotransformation catalyst. Meanwhile, these findings 323 
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suggest that further examples of novel, and potentially latent, enzymatic pericyclic 324 
reactions remain to be discovered in natural product biosynthetic pathways. 325 
 326 
 327 
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Methods 372 
 373 
Material, bacterial strains and culture conditions 374 
 375 
All chemicals and biomaterials were purchased from Merck (USA) or Thermo Fisher 376 
(USA) unless otherwise stated. All the enzymes were purchased from Thermo Fisher 377 
(USA) or New England Biolabs (USA). All E. coli strains were grown in liquid or on 378 
solid (1.5% agar) LB medium at 37 °C. For general maintenance of strain stocks, S. 379 
longisporoflavus was grown in grown at 30 °C 220 rpm in TSBY (30 g/L tryptic soy 380 
broth, 5 g/L yeast extract, 103 g/L sucrose) or at 30 °C on SFM agar (20 g/L soy flour, 381 
20 g/L D-mannitol, 20 g/L agar).  382 
 383 
General DNA manipulation techniques  384 
 385 
PCR amplification of DNA was performed using Q5 DNA polymerase (New England 386 
Biolabs). DNA cloning was performed using standard restriction digestion or 387 
isothermal DNA assembly. Sanger sequencing was used to confirm the sequence of 388 
all cloned DNA. Genomic DNA from S. longisporoflavus was isolated by chloroform 389 
extraction followed by isopropanol precipitation and washed using 70% ethanol. 390 
Mutagenesis of tsn15 was performed for tsn15-E109A, tsn15-D122A, and tsn15-391 
W190A using a Quikchange II mutagenesis kit (Agilent, USA). The remaining tsn15 392 
mutant constructs were ordered from GenScript (China).   393 
 394 
 395 
Deletion and complementation of tsn11 and tsn15 in S. longisporoflavus  396 
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 397 
The deletions of tsn11 and tsn15 were made in the coding region to avoid introducing 398 
a frameshift that could have deleterious polar effects on downstream gene expression. 399 
Genomic DNA of S. longisporoflavus was purified and used as a template for all PCR 400 
amplification necessary to create a tsn11 gene-deletion plasmid construct. 2 kbp 401 
stretches of the genomic DNA upstream and downstream of tsn11 were amplified 402 
using tsn11_Up_Fw/tsn11_Up_Rv and tsn11_Dn_Fw/tsn11_Dn_Rv primers, 403 
respectively. The primers contained additional nucleotides on their 5’ ends that 404 
enabled the two fragments to be joined and ligated into the NdeI site of pYH7 using 405 
isothermal DNA assembly43, producing the recombinant construct pYH7-tsn11 in 406 
which 1356 nt of the tsn11 coding frame was deleted. pYH7-tsn11 was transformed 407 
into E. coli ET12657/pUZ800244 cells which were mixed into a fresh liquid culture of 408 
S. longisporoflavus. After mixing, the cell mixture was plated on SFM agar 409 
supplemented with 20 mM MgCl2 and incubated at 30 oC for 16 h. The SFM agar was 410 
then overlayed with 1 mL of sterilised water containing nalidixic acid and apramycin 411 
(0.875 mg of each per 35 mL plate). After several days of growth at 30 °C, 412 
apramycin-resistant S. longisporoflavus exconjugants containing a single homologous 413 
crossover event with pYH7-tsn11 appeared. These single colonies were grown of 414 
SFM agar lacking antibiotics to promote a second recombination event via plasmid 415 
loss. S. longisporoflavus exconjugants that had undergone a double homologous 416 
crossover event (those that had regained apramycin sensitivity) were screened using 417 
tsn11_KO_Fw/tsn11_KO_Rv primers to detect the 572 bp PCR product indicative of 418 
the successful genomic deletion of tsn11. The PCR product was sequenced to confirm 419 
the S. longisporoflavus ∆tsn11 genotype.  420 
 421 
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For the deletion of Tsn15, genomic DNA of S. longisporoflavus was purified and used 422 
as a template for all PCR amplification necessary to create a tsn15 gene-deletion 423 
plasmid construct. 2 kbp stretches of the genomic DNA upstream and downstream of 424 
tsn15 were amplified using tsn15_Up_Fw/tsn15_Up_Rv and 425 
tsn15_Dn_Fw/tsn15_Dn_Rv primers, respectively. The primers contained additional 426 
nucleotides on their 5’ ends that enabled the two fragments to be joined and ligated 427 
into the NdeI site of pYH7 by Gibson assembly43, producing the recombinant 428 
construct pYH7-tsn15 in which the entire 621 bp tsn15 coding frame was deleted. The 429 
protocol for deleting tsn15 was then identical to that previously described for 430 
creationg S. longisporoflavus ∆tsn11. Exconjugants that had undergone two 431 
homologous crossing over events with pYH7-tsn15 were screened using 432 
tsn15_KO_Fw/tsn15_KO_Rv primers to detect the 713 bp PCR product indicative of 433 
the successful genomic deletion of tsn15. The PCR product was sequenced to confirm 434 
the S. longisporoflavus ∆tsn15 genotype.   435 
 436 
The S. longisporoflavus ∆tsn11 ∆tsn15 (double mutant) was created by deleting tsn15 437 
in S. longisporoflavus ∆tsn11. The same protocol for deleting tsn15 was followed, 438 
except that S. longisporoflavus ∆tsn11 rather than wildtype S. longisporoflavus 83E6 439 
was conjugated with pYH7-tsn15.  440 
  441 
To complement the S. longisporoflavus ∆tsn11 mutant, tsn11 was amplified from the 442 
genomic DNA of S. longisporoflavus using tsn11-pIB139-Fw/tsn11-pIB139-Rv 443 
primers. The amplified tsn11 was then cloned by isothermal DNA assembly at the 444 
XbaI site of pIB139, downstream of the ermE* promoter, creating pIB139-tsn11. 445 
pIB139-tsn11 was conjugated into S. longisporoflavus ∆tsn11 using E. coli 446 
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ET12657/pUZ8002. Apramycin-resistant exconjugants were selected and grown for 447 
seven days before HPLC-MS analysis. To complement the S. longisporoflavus ∆tsn15 448 
mutant, tsn15 was amplified from the genomic DNA of S. longisporoflavus using 449 
tsn15-pIB139-Fw/tsn15-pIB139-Rv primers. The amplified tsn15 was then cloned by 450 
isothermal DNA assembly at the XbaI site of pIB139, downstream of the ermE* 451 
promoter, creating pIB139-tsn15. pIB139-tsn15 was conjugated into S. 452 
longisporoflavus ∆tsn15 using E. coli ET12657/pUZ8002.  453 
 454 
Analysis of metabolites from S. longisporoflavus  455 
 456 
To test for the production of either tetronasin 1 or intermediate 3, a colony of S. 457 
longisporoflavus (or of a S. longisporoflavus deletion mutant/complementation strain) 458 
was inoculated into tsn-medium-A (30 g/L tryptic soy broth, 3 g/L CaCO3, trace 459 
elements: 4 mg/L FeSO4, 4 mg/L ZnSO4, 0.6 mg/L CuSO4, 0.4 mg/L MnSO4, 0.4 460 
mg/L KMoO4) and grown for two days at 30 °C 200 rpm. The culture was then plated 461 
onto petri dishes containing tsn-medium-B (30 g/L tryptic soy broth, 3 g/L CaCO3, 462 
100 g/L dextrin, 20 g/L agar, trace elements: 4 mg/L FeSO4, 4 mg/L ZnSO4, 0.6 mg/L 463 
CuSO4, 0.4 mg/L MnSO4, 0.4 mg/L KMoO4) and grown at 30 °C for seven days. The 464 
agar and cells were then extracted using ethyl acetate. The ethyl acetate was 465 
evaporated under reduced pressure and the organic extract was dissolved in methanol 466 
for analysis HPLC (Hewlett Packard, Agilent Technologies1200 series) coupled to a 467 
mass spectrometer (Thermo Finnigan MAT LTQ). The HPLC-MS was fitted with a 468 
250 mm x 4.6 mm 5µm C18 reverse-phase column (5μ OSD3, 100Å. Phenomenex, 469 
USA). The mobile phase comprised of 20 mM ammonium acetate and increasing 470 
methanol at a flow rate of 0.7 mL/min: 0-5 min, 5-75% methanol; 5-30 min, 75-95% 471 
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methanol, 30-34 min, 95% methanol 35-36 min, 95-5% methanol. Normalised 472 
collision energy of 35% was used for the molecular fragmentation of tetronasin. High-473 
resolution mass spectra were obtained using a Vion IMS QTOF (Waters, USA) 474 
operated by the mass spectrometry service of the Department of Chemistry, 475 
University of Cambridge. 476 
 477 
Heterologous expression of cyclase genes in E. coli 478 
 479 
The tsn15, tsn11, tmn9, and tmn8 genes were each amplified by PCR. The PCR 480 
products were individually digested using NdeI and XhoI and cloned between the 481 
NdeI and XhoI sites of pET28a(+), in-frame with the N-terminal polyhistidine tag 482 
(MGSSHHHHHHSSGLVPRGSH). Each expression plasmid was individually used to 483 
transform chemically competent E. coli BL21 (DE3) cells (Thermo Fisher, USA). A 484 
single colony from each E. coli BL21 (DE3) transformant was cultured at 37 °C, 200 485 
rpm in lysogeny-broth (LB) containing 50 µg/mL kanamycin. Once the culture had 486 
reached an A600 = 0.5, protein expression was induced by adding isopropyl β-D-1-487 
thiogalactopyranoside (IPTG) to a final concentration of 0.5 mM. The culture was 488 
then incubated for 16 h at 20 °C, 200 rpm. The cells were harvested by centrifugation 489 
and resuspended in 30 mL of 20 mM Tris-Cl pH 7.9 buffer, 500 mM NaCl). Cells 490 
were lysed using an Emulsiflex C5 (Avestin, Canada) according to the manufacturer’s 491 
instructions. The insoluble fraction was removed by centrifugation and the soluble 492 
fraction was passed though Ni-affinity resin (Qiagen, Germany) to bind the 493 
recombinant protein. Lysis buffer containing increasing imidazole concentrations (50-494 
400 mM) was used to remove contaminants and subsequently elute pure recombinant 495 
protein (monitored by SDS-PAGE). Fractions containing the purified recombinant 496 
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proteins were concentrated using Amicon Ultra-15 centrifugal filter units (Merck 497 
Millipore, USA) and the buffer was exchanged into 20 mM Tris-Cl, 100 mM NaCl, 498 
10% glycerol pH 7.9 using a PD-10 column (GE Healthcare, USA) according to the 499 
manufacturer’s instructions. Protein concentration was determined by the Bradford 500 
assay using a BSA standard curve. Protein aliquots were then snap frozen in liquid 501 
nitrogen and stored at -80°C.  502 
 503 
Protein quaternary structure analysis by analytical ultracentrifugation   504 
 505 
Analytical ultracentrifugation (AUC) was used to measure the molecular weight of 506 
Tsn11 and Tsn15 in solution. Tsn15 and Tsn11 were purified and individually 507 
concentrated to 0.75 mg/mL in a final volume of 800 µL. When Tsn11 and Tsn15 508 
were sedimented together, each was present in the same chamber at a concentration of 509 
0.75 mg/mL. AUC experiments were performed using an Optima XL-I (Beckman 510 
Coulter, USA) centrifuge fitted with an An60 Ti four-hole rotor. Absorbance and 511 
interference data were acquired in the continuous mode at time intervals of 170 s and 512 
at a rotor speed of 40,000 rpm, at 20 °C with systematic noise subtracted, but without 513 
averaging. The density and viscosity of the buffer (20 mM Tris-Cl pH 7.9, 100 514 
mM/150 mM NaCl) and the partial specific volume of the protein were both 515 
calculated using Sednterp32. The multi-component sedimentation coefficient 516 
distributions were obtained from 128 scans by direct boundary modeling of the Lamm 517 
equation using Sedfit v.14.1.   518 
 519 
 520 
 521 
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Isolation of Intermediate 3 for NMR analysis 522 
 523 
Intermediate 3 was isolated from S. longisporoflavus ∆tsn11. Well-grown S. 524 
longisporoflavus ∆tsn11 colonies were inoculated into 5 mL of tsn-medium-A and 525 
grown for two days at 30 °C and 200 rpm. The cultures were then inoculated into 526 
flasks containing 50 mL of tsn-medium-A and grown for an additional two days at 527 
30 °C 200 rpm, or until a thick mycelial culture had grown. These cells were plated 528 
on 400 12 cm x 12 cm agar plates each containing 50 mL of tsn-medium-B agar (30 529 
g/L tryptic soy broth, 3 g/L CaCO3, 100 g/L dextrin, 20 g/L agar, trace elements: 4 530 
mg/L FeSO4, 4 mg/L ZnSO4, 0.6 mg/L CuSO4, 0.4 mg/L MnSO4, 0.4 mg/L KMoO4) 531 
and grown for seven days at 30 °C. The agar was then cut into small squares and 532 
combined in a large glass flask where it was extracted three times by submerging in 2 533 
L of ethyl acetate . The ethyl acetate was evaporated under reduced pressure to yield 7 534 
g of a brown crude organic extract. The crude extract was dissolved in 8 mL of 535 
methanol and loaded onto 8 10g/70 mL C18 reverse-phase Isolute cartridges (Biotage, 536 
Sweden) according to the manufacturer’s instructions. Fractions were eluted from the 537 
columns using a mixture of 20 mM ammonium acetate and increasing methanol. 538 
Fractions containing intermediate 3 were identified by HPLC-MS and pooled together 539 
(1.15 g in total) before a second round of SPE purification. The final purification step 540 
was performed using an Infinity II semipreparative HPLC (Agilent, USA) fitted with 541 
a Phenomenex (USA) C18 Prodigy column (5 µm ODS-3 100Å, 250 x 10 mm). 542 
Gradient elution of intermediate 3 was achieved using a mobile phase of 5 mM 543 
ammonium acetate and methanol with a flow rate of 3 mL/min: 0-5 min, 5-75% 544 
methanol; 5-15 min, 75-85% methanol; 15-19 min, 85-100% methanol; 19-20 min, 545 
100-5% methanol. Fractions containing intermediate 3 were identified by detecting its 546 
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characteristic chromophore (λmax = 236) nm and pooled together, followed by solvent 547 
evaporation under reduced pressure. The dried extract was dissolved in ethyl acetate 548 
to remove the ammonium acetate, followed by freeze-drying to yield purified 3 (12.5 549 
mg). For structural determination, 3 was dissolved in deuterated chloroform and 550 
analysed using a 500 MHz DCH Cryoprobe Spectrometer (Bruker, USA).  551 
 552 
 553 
Isolation of Intermediate 4 for NMR analysis  554 
 555 
Intermediate 4 was isolated from an in vitro reaction of 3 and Tsn11. The assay 556 
mixture (60 mL in total) contained: 20 mM Tris-Cl, 100 mM NaCl, pH 7.9 containing 557 
50 µM Tsn11, 400 µM of 3, and 5% v/v methanol. After incubation at 30 °C for 1.5 h, 558 
the reaction mixture was extracted six times with 30 mL of ethyl acetate. The ethyl 559 
acetate was evaporated, and the organic residue was dissolved in methanol. The 560 
extract was chromatographed on semipreparative HPLC as described above. Fractions 561 
containing intermediate 4 were identified by detecting its characteristic chromophore 562 
(λmax = 254) nm and pooled together for solvent evaporation. The dried residue was 563 
dissolved in ethyl acetate to remove the ammonium acetate, followed by freeze-564 
drying to yield purified 4 (3.3 mg). For structural determination, 4 was dissolved in 565 
deuterated methanol and analysed using a 500 MHz DCH NMR Cryoprobe 566 
Spectrometer (Bruker, USA).  567 
 568 
In vitro assays  569 
 570 
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In vitro activity assays of Tsn11 and Tsn15 were performed in 20 mM Tris-Cl buffer, 571 
100 mM NaCl, 5% v/v methanol pH 7.9. Typically, reaction volumes were 100 µL 572 
and contained 200 µM of 3 or 4. Tsn11 and/or Tsn15 were added to a final 573 
concentration of 5 µM. The reactions were carried out at 30 °C for 1 h unless stated 574 
otherwise. The reactions were terminated by adding 400 µL of methanol before being 575 
completely dried under reduced pressure. The dried extract was redissolved in 100 µL 576 
methanol and analysed by HPLC fitted with a Phenomenex C18 Prodigy column (5 577 
µm ODS-3 100Å, 250 x 10 mm) using a gradient program of 20 mM ammonium 578 
acetate and increasing methanol at a flow rate of 3 mL/min: 0-5 min, 5-75% 579 
methanol; 5-15 min, 75-85% methanol; 15-19 min, 85-100% methanol; 19-20 min, 580 
100-5% methanol. For all in vitro assays, the identity of intermediates 3 and 4 were 581 
confirmed by their unique UV chromophores and MS3 fragmentation patterns. For 582 
analysis of the Tsn11 sodium dithionite assays and the Tsn15 point mutation assays, a 583 
Poroshell 120, EC-C18, 27 µM, 46 x 100 mm (Agilent, USA) column eluted with 5 584 
mM ammonium acetate and methanol at 1 mL/min: 0-5 min, 5-75% methanol; 5-15 585 
min 75-95% methanol; 15-19 min, 95% methanol; 19-20 min, 95-5% methanol. 586 
When the Tsn11 activity assay was conducted in the presence of sodium dithionite, 587 
100 µM of 3 was used with 1 µM of Tsn11 and 1 mM of sodium dithionite. Parallel 588 
reactions were carried out and terminated at 0 min, 2 min, 4 min, and 8 min, 589 
respectively.  590 
 591 
Protein crystallisation  592 
 593 
For protein crystallisation, tsn15 was expressed in E. coli BL21 (λDE3) and purified 594 
by nickel-affinity chromatography as previously described. The proteins were further 595 
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purified using a preparative gel-filtration ÄKTA (GE Healthcare Lifescience, USA) 596 
connected to a Hiload 16/60 column packed with Superdex 200 resin. Fractions 597 
containing Tsn15 were pooled and concentrated. Tsn15 was concentrated to 15 598 
mg/mL (20 mM Tris-Cl pH 7.9 buffer, 100 mM NaCl) and crystallised in 0.1 M 599 
PCTP (0.1 M each sodium proprionate, sodium cacodylate trihydrate, and bis-Tris 600 
propane) pH 6.0, 25% PEG 1500 using the sitting-drop, vapour-diffusion method at 601 
19 ºC. The Tsn15-substrate complex was crystallised using hanging-drop, vapor-602 
diffusion method at 18 ºC. To obtain the protein complex, a solution composed of 603 
Tsn15 protein (15 mg/mL in 20 mM Tris-Cl pH 7.9 buffer, 0.5 M NaCl) and 10 mM 604 
of 4 was incubated for 10 minutes and then crystallised in 0.1 M PCTP pH 6.0 buffer, 605 
27% PEG 1500. To solve the phases for the Tsn15 structure, a selenomethionine 606 
labeled version of Tsn15 (SeMet-Tsn15) was created and the structure was 607 
determined using the Single Anomalous Dispersion (SAD) method. To achieve this, E. 608 
coli BL21 (λDE3) cells transformed with pET28a(+)-tsn15 were cultured in M9 609 
medium. Once the culture had reached A600 = 0.5, 0.1 g/L L-lysine, 0.1 g/L L-610 
threonine, 0.1 g/L L-phenylalanine, 0.05 g/L L-leucine, 0.05 g/L L-isoleucine, 0.05 611 
g/L L-valine were added to the growing culture, followed by 0.06 g/L of L-612 
selenomethionine. SeMet-Tsn15 was purified and exchanged into buffer containing 613 
20 mM Tris-Cl pH 7.9, 100 mM NaCl, 2 mM EDTA, and 2 mM tris(2-614 
carboxyethyl)phosphine (TCEP), then crystallised as before. Crystals were harvested 615 
from the crystallisation drop and transferred into a cryoprotecting solution containing 616 
the crystallisation solution and 25-27% ethylene glycol. The crystals were then flash-617 
frozen in liquid nitrogen using nylon loops. X-ray diffraction data for SeMet-Tsn15 618 
were collected at the Diamond Light Source (DLS) I04 beamline, Oxford, UK, while 619 
for the complex Tsn15-substrate data were collected at PETRAIII, beamline 13, 620 
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Hamburg, Germany. The X-ray data processing was performed using XDS33and 621 
scaled using Aimless34 from CCP4 suite35. The phases for SeMet-Tsn15 was solved 622 
using AutoSol36 from Phenix suite37. The structural model was initially built by 623 
AutoBuild38 also from PHENIX suite37. The phases for the Tsn15-substrate complex 624 
was determined by molecular replacement using the program Phaser39 from Phenix 625 
suite37. The SeMet-Tsn15 structure was used as the search model for molecular 626 
replacement. Both SeMet-Tsn15 and Tsn15-substrate complex models were refined 627 
using Phenix.refine40 and further visual inspection and real space refinement was 628 
performed by COOT41. The stereochemical quality of the models was assessed using 629 
MolProbity42. The protein structure figures were prepared using PyMOL Molecular 630 
Graphics System, Version 2.0 Schrödinger, LLC. 631 
 632 
Revised sequence of Tsn11  633 
 634 
Closer examination of the tsn11 gene compared to the deposited sequence revealed 635 
the start codon to be an additional 12 bp 5’ of the previously annotated start codon. 636 
The new start codon was a methionine (ATG) rather than a leucine (TTG) and was six 637 
bp downstream from a likely Shino-Delgarno sequence (GGAAGAA). The revised 638 
protein sequence of the updated Tsn11 is presented below. 639 
 640 
 641 
 642 
 643 
 644 
 645 
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Tsn11: 646 
MEIPLTGTVVIAGAGPVGLFLASELRLAGVEAVVLERSPKANEHTVGGTLHARTADL647 
FDQRGIMDTLRAGNPPLWPRLHFASYWLDLAPHMEDEYSLLLPQQYTEEMLEAHATE648 
LGADIRRGHTCVSLTQDADGVTVGVRADSGDYELRGAYLVGCDGGDSTVRELAAFPV649 
QESGPRWYGLLADVESIEGDWHPGNYPGGQFAVIRSPHEGGPSRIMTLEFNETTQPP650 
PADQPVSVEEVIASTERITGRTPVVGEVQWLHRYTNTTREAENYRQGRVFVAGDAAH651 
LHVAFAGHGLSTGLHDAANLGWKLAAVLDGRAPDSLLDTYDEERRPVGHRACVFTQS652 
QMALLTQGQQLDILRQLFTDLVKLPEVNHHLITTVTDVRYALDGAEKEDTHPLLGRP653 
VPNQLVKDADGQATAVAEALRAGRGVLIDLTDGAAALPDTSGRRGHLDSVSRGPADA654 
VDATALLVRPDGFVAWAATADTGNDGLEPALRRWFGDTA 655 
 656 
Revised Sequence of Tmn9 657 
 658 
During cloning of tmn9 it was noted that the sequence differed from that previously 659 
published15 (confirmed by sequencing independent PCR reactions). The revised Tmn9 660 
protein sequence is as follows:  661 
 662 
Tmn9: 663 
MSEPVVVVGAGPAGLMLACELAMRDVPAVLVDIHPTQRAEAPAMAINAGTLEMLDQR664 
GLAAGLREGTVTFPEVRFADLRLAFEKVQGPREPTHMVLQSRLEKVLIDRAVELGVD665 
LRWATRLTGFEEAADGSGVTVTLASDAGEEQLRCRYLVGCDGRESIVRKQAGIDYVG666 
DDWVIVRGIVGDVAINREDVAPEQYGLSYTDNGDQFLGAPLSPDVMRVFSAEFSTEP667 
PEFEDGPATLEQLGDAVKRLTGKELKATEAHWLQHYSIVTRNAEQYRKGRVFIAGDA668 
AHVHYPYNGQGLGTAIGDAVNLGWKIAAEVHGWAPADLLDSYHVERHLAGRLACMNI669 
QAQLALLYPRPLARYMREMMGEFLKFDEVNVFLAEIVTNLGPAVPIAYEGVPEPVEG670 
DRLLGRRLPKVQIKTADGDMGVAETLQSGRGVLLDLSGDASAQEESGWADRVDVVRA671 
QPVPDLPGTLLLRPDGCVAWHDGGGWGQDELRTALRTWFGAPTG 672 
 673 
Sequence of Tsn15 674 
Prior to the submission of this manuscript a different ORF in the tetronasin gene 675 
cluster, an ABC transporter, was named Tsn15. The Tsn15 described in this paper 676 
was not annotated. As such, the ABC transporter has been renamed Tsn15b and 677 
Tsn15 now refers to the [4+2] cyclase homologue. For clarity the DNA and protein 678 
sequence of Tsn15 are presented below: 679 
 680 
tsn15: 681 
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ATGACCACTTCCATCGATCCGACGACCCCGCTGACCTACAACCCCGTCATCGACGCG682 
CTCGTCGGCTCGTGGCGCCAGATCATCGACGCCGACTACTCGGCGGACGACACCCGG683 
CTGCCCGATCTCGCCGTGCTGGCCCGCTCCACCGCGCGGGCGGTCGCGGCTGCCGTA684 
CCCCGTCCGCTCGCGGAGATCTCGGCCCCGGACGCGCCGGACGAGCGCGGCGAACTC685 
GTGCTGCTGGAGAAGGTGATCCAGGAAGTGGCCGACCGCGAGTACACCCCGCTGAGC686 
CCCGAGGGGCCGAGCGTCGGGGACCTCGTCCTGGTGACGGAGAAGATCTACAACTCC687 
GACCGCGAGGAGATCGGCGCGGACACCGGGCGGCTGCGGATCATCCGCAAGGACCCG688 
GAGACCGGGCACCACTTCACGGTCTCGCTCGTCACGTCCACGGTGCAGGGCAACAAG689 
CTGTTCGCCTTCGGCTACACCGAGATGGAGGCCCAGCTCGCCGGGGGCCGCACCACC690 
ATCCAGGTCGCCTGCTGGGACGGCCCCTGGGCCGGCATGAGCGGCACCCTGTCCTGG691 
GTCATCAACTCCATGACGGCCGCCGAGTCGCGGTACGAGCTGCGCCGCTGA 692 
 693 
Tsn15: 694 
MTTSIDPTTPLTYNPVIDALVGSWRQIIDADYSADDTRLPDLAVLARSTARAVAAAV695 
PRPLAEISAPDAPDERGELVLLEKVIQEVADREYTPLSPEGPSVGDLVLVTEKIYNS696 
DREEIGADTGRLRIIRKDPETGHHFTVSLVTSTVQGNKLFAFGYTEMEAQLAGGRTT697 
IQVACWDGPWAGMSGTLSWVINSMTAAESRYELRR 698 
 699 
Interception and detection of PKS-bound polyketide intermediates 700 
 701 
All S. longisporoflavus strains were grown in 10 mL tsn-medium A for 2 days at 30 702 
°C at 200 rpm. Seed cultures (100 µl) were used to inoculate tsn-medium A (10 mL of 703 
liquid culture, in duplicate, in 50 mL Erlenmeyer flasks with springs). They were then 704 
incubated at 30 °C for 5 days. After the first day of incubation, the probe (methyl 6-705 
decanamido-2-fluoro-3-oxohexanoate (6), final concentration: 1 mM) was dissolved 706 
in 80 µl of MeOH and added portionwise over 4 days (20 µl each day, days 2-5). 707 
Control liquid cultures omitting methyl 6-decanamido-2-fluoro-3-oxohexanoate were 708 
also prepared (in duplicate copy). After 5 days of fermentation, the liquid cultures 709 
were extracted with ethyl acetate (20 mL). The extracts were concentrated and the 710 
residues were redissolved in HPLC-grade methanol (1 mL) for mass spectrometry 711 
analysis. 712 
 713 
HPLC-HR-ESI-MS analyses of S. longisporoflavus extracts were carried out on an 714 
LTQ-T Orbitrap Fusion instrument. Reverse phase chromatography was used to 715 
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separate the mixtures prior to MS analysis. Two columns were utilised: an Acclaim 716 
PepMap µ-precolumn cartridge 300 µm i.d. x 5 mm 5 μm 100 Å and an Acclaim 717 
PepMap RSLC 75 µm x 15 cm 2 µm 100 Å (Thermo Scientific). The columns were 718 
installed on an Ultimate 3000 RSLCnano system (Dionex). Mobile phase buffer A 719 
was 0.1% aqueous formic acid and mobile phase B was composed of 100% 720 
acetonitrile containing 0.1% formic acid. Samples were loaded onto the µ-precolumn 721 
equilibrated in 50% aqueous acetonitrile containing 0.1% trifluoroacetic acid for 8 722 
min at 10 µL min-1. After which compounds were eluted onto the analytical column 723 
following a 75 min gradient for which the mobile phase B concentration was 724 
increased from 50% B to 80% over 15 min, then maintained at 80% B for 50 minutes, 725 
then decreased to 50% over 1 min, followed by a 9 min wash at 50% B. Species were 726 
analysed by electrospray ionisation mass spectrometry. Survey scans of precursors 727 
from 150 to 1500 m/z were performed at 60K resolution (at 200 m/z) with a 4 × 105 728 
ion count target. Tandem MS was performed by isolation at 1.6 Th with the 729 
quadrupole, HCD fragmentation with normalised collision energy of 32, and rapid 730 
scan MS analysis in the ion trap. The MS/MS ion count target was set to 2 x 105 and 731 
the maximum injection time was 50 ms. A filter targeted inclusion mass list was used 732 
to select the precursor ions.  733 
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All other data that supports the findings of this study is available from the 739 
corresponding author upon reasonable request.  740 
 31
 741 
All correspondence should be addressed to pfl10@cam.ac.uk 742 
Acknowledgements  743 
R.L was supported by the Woolf Fisher Trust and the Cambridge Commonwealth 744 
European and International Trust. M.V.B.D was supported by São Paulo Research 745 
Foundation (FAPESP) grants 2015/09188-8, 2017/50140-4 and 2018/00351-746 
1. F.C.R.P was supported by a CNPq (National Council for Scientific and 747 
Technological Development) fellowship 141090/2016-2. M.T and R.J gratefully 748 
acknowledge EPSRC (DTA PhD studentship to R.J.); BBSRC (project grant 749 
BB/J007250/1 to M. T.); and the FAPESP-Warwick Joint Fund (for a SPRINT award 750 
to M.V.B.D. and M.T.). 751 
Author contributions 752 
R.L., P.F.L., F.J.L., M.T. and M.V.B.D. developed the hypothesis and designed the 753 
study. Y.D., Y.S., and M.S. cloned, sequenced and analyzed gene clusters; R.L., Y.S., 754 
H.H., carried out gene deletions, M.T. and R.J. carried out and analysed experiments 755 
with chain-terminating probes; R.L. carried out protein expression and purification, in 756 
vitro experiments and compound isolation; R.L. and F.J.L. performed compound 757 
characterisation. F.C.R.P., R.L. and M.V.B.D. solved crystal structures. All authors 758 
analysed and discussed the results. P.F.L., R.L., and F.C.R.P. prepared the manuscript. 759 
Competing Interests   760 
The authors declare no competing interests 761 
References: 762 
 32
1. Diels, O. & Alder, K. Synthesen in der hydroaromatischen Reihe. Justus Liebigs 763 
Annalen der Chemie 460, 98–122 (1928). 764 
2. Corey, E. J. Catalytic Enantioselective Diels-Alder reactions: Methods, 765 
Mechanistic Fundamentals, Pathways, and Applications. Angew. Chem. Int. Ed. 766 
Engl. 41, 1650–1667 (2002). 767 
3. Lichman, B. R., O’Connor, S. E. & Kries, H. Biocatalytic Strategies Towards [4+ 768 
2] Cycloadditions. Chem. Eur. J. 25, 6864-6877 (2019). 769 
4. Jeon, B., Wang, S.-A., Ruszczycky, M. W. & Liu, H. Natural [4 + 2]-Cyclases. 770 
Chem. Rev. 117, 5367–5388 (2017). 771 
5. Ma, S. M. et al. Complete Reconstitution of a Highly Reducing Iterative 772 
Polyketide Synthase. Science 326, 589–592 (2009). 773 
6. Kasahara, K. et al. Solanapyrone Synthase, a Possible Diels–Alderase and 774 
Iterative Type I Polyketide Synthase Encoded in a Biosynthetic Gene Cluster 775 
from Alternaria solani. ChemBioChem 11, 1245–1252 (2010). 776 
7. Kim, H. J., Ruszczycky, M. W., Choi, S., Liu, Y. & Liu, H. Enzyme-catalysed 777 
[4+2] Cycloaddition is a Key Step in the Biosynthesis of Spinosyn A. Nature 473, 778 
109–112 (2011). 779 
8. Fage, C. D. et al. The Structure of SpnF, a Standalone Enzyme that Catalyzes 780 
[4+2] Cycloaddition. Nat. Chem. Biol. 11, 256–258 (2015). 781 
9. Hashimoto, T. et al. Biosynthesis of Versipelostatin: Identification of an Enzyme-782 
Catalyzed [4+2]-Cycloaddition Required for Macrocyclization of Spirotetronate-783 
Containing Polyketides. J. Am. Chem. Soc. 137, 572–575 (2015). 784 
10. Byrne, M. J. et al. The Catalytic Mechanism of a Natural Diels–Alderase 785 
Revealed in Molecular Detail. J. Am. Chem. Soc. 138, 6095-6098 (2016).   786 
 33
11. Tian, Z. et al. An Enzymatic [4+2] Cyclization Cascade Creates the Pentacyclic 787 
Core of Pyrroindomycins. Nat. Chem. Biol. 11, 259–265 (2015). 788 
12. Zhang, Z. et al. Enzyme-Catalyzed Inverse-Electron Demand Diels–Alder 789 
Reaction in the Biosynthesis of Antifungal Ilicicolin H. J. Am. Chem. Soc. 141, 790 
5659–5663 (2019). 791 
13. Cogan, D. P. et al. Structural Insights into Enzymatic [4+2] aza-Cycloaddition in 792 
Thiopeptide Antibiotic Biosynthesis. Proc. Natl. Acad. Sci. 114, 12928–12933 793 
(2017). 794 
14. Ohashi, M. et al. SAM-dependent Enzyme-Catalysed Pericyclic Reactions in 795 
Natural Product Biosynthesis. Nature 549, 502–506 (2017). 796 
15. Demetriadou, A. K. et al. Biosynthesis of the Polyketide Polyether Antibiotic ICI 797 
139603 in Streptomyces longisporoflavus from 18O-labelled Acetate and 798 
Propionate. J. Chem. Soc., Chem. Commun. 19, 408–410 (1985). 799 
16. Demydchuk, Y. et al. Analysis of the Tetronomycin Gene Cluster: Insights into 800 
the Biosynthesis of a Polyether Tetronate Antibiotic. ChemBioChem 9, 1136–801 
1145 (2008). 802 
17. Sun, Y., Hong, H., Gillies, F., Spencer, J. B. & Leadlay, P. F. Glyceryl-S-Acyl 803 
Carrier Protein as an Intermediate in the Biosynthesis of Tetronate Antibiotics. 804 
ChemBioChem 9, 150–156 (2008). 805 
18. Hailes, H. C., Jackson, C. M., Leadlay, P. F., Ley, S. V. & Staunton, J. 806 
Biosynthesis of Tetronasin: Part 1 Introduction and Investigation of the Diketide 807 
and Triketide Intermediates Bound to the Polyketide Synthase. Tetrahedron Lett. 808 
35, 307–310 (1994). 809 
19. Boons, G.-J. et al. Novel Polyene Cyclisation Routes to the Acyl Tetronic Acid 810 
Ionophore Tetronasin (ICI M139603). Tetrahedron Lett. 35, 323–326 (1994). 811 
 34
20. Riva, E. et al. Chemical Probes for the Functionalization of Polyketide 812 
Intermediates. Angew. Chem. Int. Ed. 53, 11944–11949 (2014). 813 
21. Tosin, M., Smith, L. & Leadlay, P. F. Insights into Lasalocid A Ring Formation 814 
by Chemical Chain Termination in vivo. Angew. Chem. Int. Ed. Engl. 50, 11930–815 
11933 (2011). 816 
22. Zheng, Q. et al. Structural Insights into a Flavin-Dependent [4+2] Cyclase that 817 
Catalyzes trans-Decalin Formation in Pyrroindomycin Biosynthesis. Cell Chem. 818 
Biol. 25, 718-727 (2018). 819 
23. Bosserman, M. A., Downey, T., Noinaj, N., Buchanan, S. K. & Rohr, J. 820 
Molecular Insight into Substrate Recognition and Catalysis of Baeyer–Villiger 821 
Monooxygenase MtmOIV, the Key Frame-Modifying Enzyme in the 822 
Biosynthesis of Anticancer Agent Mithramycin. ACS Chem. Biol. 8, 2466–2477 823 
(2013). 824 
24. Vieweg, L., Reichau, S., Schobert, R., Leadlay, P. F. & Süssmuth, R. D. Recent 825 
Advances in the Field of Bioactive Tetronates. Nat. Prod. Rep. 31, 1554–1584 826 
(2014). 827 
25. Jiang, X. & Wang, R. Recent Developments in Catalytic Asymmetric Inverse-828 
Electron-Demand Diels–Alder Reaction. Chem. Rev. 113, 5515–5546 (2013). 829 
26. Pałasz, A. Recent Advances in Inverse-Electron-Demand Hetero-Diels–Alder 830 
Reactions of 1-oxa-1,3-Butadienes. Top. Curr. Chem (Cham). 374, 24 (2016).  831 
27. Zheng, Q. et al. Enzyme-Dependent [4+2] Cycloaddition Depends on Lid-like 832 
Interaction of the N-Terminal Sequence with the Catalytic Core in PyrI4. Cell 833 
Chemical Biology 23, 352–360 (2016). 834 
 35
28. Hofmann, E., Zerbe, P. & Schaller, F. The Crystal Structure of Arabidopsis 835 
thaliana Allene Oxide Cyclase: Insights into the Oxylipin Cyclization Reaction. 836 
Plant Cell 18, 3201–3217 (2006). 837 
29. Yoeun, S., Cho, K. & Han, O. Structural Evidence for the Substrate Channeling of 838 
Rice Allene Oxide Cyclase in Biologically Analogous Nazarov Reaction. Front. 839 
Chem. 6, 500 (2018) DOI: 10.3389/fchem.2018.00500. 840 
30. Costa, K. C., Glasser, N. R., Conway, S. J. & Newman, D. K. Pyocyanin 841 
Degradation by a Tautomerizing Demethylase Inhibits Pseudomonas aeruginosa 842 
Biofilms. Science 355, 170–173 (2017). 843 
31. Wilkinson, C. J. et al. Increasing the Efficiency of Heterologous Promoters in 844 
Actinomycetes. J. Mol. Microbiol. Biotechnol. 4, 417–426 (2002). 845 
32. Harding S. E., Rowe S. E. Analytical Ultracentrifugation in Biochemistry and 846 
Polymer Science.  Royal Society of Chemistry: Cambridge (United Kingdom), 847 
(1992).  848 
33. Kabsch, W. XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132 (2010). 849 
34. Evans, P. R. & Murshudov, G. N. How Good are my Data and what is the 850 
Resolution? Acta Crystallogr. D Biol. Crystallogr. 69, 1204–1214 (2013). 851 
35. Winn, M. D. et al. Overview of the CCP4 Suite and Current Developments. Acta 852 
Crystallogr. D Biol. Crystallogr. 67, 235–242 (2011). 853 
36. Terwilliger, T. C. et al. Decision-Making in Structure Solution using Bayesian 854 
Estimates of Map Quality: the PHENIX AutoSol Wizard. Acta Crystallogr. D 855 
Biol. Crystallogr. 65, 582–601 (2009). 856 
37. Adams, P. D. et al. The Phenix Software for Automated Determination of 857 
Macromolecular Structures. Methods 55, 94–106 (2011). 858 
 36
38. Terwilliger, T. C. et al. Iterative Model Building, Structure Refinement and 859 
Density Modification with the PHENIX AutoBuild Wizard. Acta Crystallogr. D 860 
Biol. Crystallogr. 64, 61–69 (2008). 861 
39. McCoy, A. J. Solving Structures of Protein Complexes by Molecular 862 
Replacement with Phaser. Acta Crystallogr. D Biol. Crystallogr. 63, 32–41 863 
(2007). 864 
40. Afonine, P. V. et al. Towards Automated Crystallographic Structure Refinement 865 
with phenix.refine. Acta Crystallogr. D Biol. Crystallogr. 68, 352–367 (2012). 866 
41. Emsley, P. & Cowtan, K. Coot: Model-Building Tools for Molecular Graphics. 867 
Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132 (2004). 868 
42. Chen, V. B. et al. MolProbity: All-Atom Structure Validation for Macromolecular 869 
Crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12–21 (2010). 870 
43. Gibson, D. G. et al. Enzymatic Assembly of DNA Molecules up to Several 871 
Hundred Kilobases. Nat. Methods 6, 343–345 (2009). 872 
44. MacNeil, D. J. et al. Analysis of Streptomyces avermitilis Genes Required for 873 
Avermectin Biosynthesis Utilizing a Novel Integration Vector. Gene 111, 61–68 874 
(1992). 875 
45. Sievers, F. et al. Fast, Scalable Generation of High‐Quality Protein Multiple 876 
Sequence Alignments using Clustal Omega. Mol. Syst. Biol. 7, 539 (2011). 877 
46. Laskowski, R. A. et al. PDBsum: a Web-Based Database of Summaries and 878 
Analyses of all PDB Structures. Trends Biochem. Sci. 22, 488–490 (1997). 879 
47. Tian, W., Chen, C., Lei, X., Zhao, J. & Liang, J. CASTp 3.0: Computed Atlas of 880 
Surface Topography of Proteins. Nucleic Acids Res. 46, 363–367 (2018). 881 
48. Bulsing, J. M. et al. Biosynthesis of the Polyketide Antibiotic ICI139603 in 882 
Streptomyces longisporoflavus: Assignment of the 13C NMR Spectrum by Two-883 
 37
Dimensional Methods, and Determination of the Origin of the Carbon Atoms. J. 884 
Chem. Soc., Chem. Commun. 19, 1301–1302 (1984). 885 
49. Gelin, S. & Pollet, P. Tautomerism in Acyl Tetronic Acids. Tetrahedron Lett. 21, 886 
4 (1980). 887 
 888 
 889 
 890 
 891 
 892 
 893 
 894 
 895 
 896 
 897 
 898 
 899 
 900 
 901 
 902 
 903 
 904 
 905 
 906 
 907 
 908 
 909 
 38
 910 
 911 
 912 
 913 
 914 
 915 
 916 
 917 
 918 
a 
c 
b 
O
O
O OH
O
OMe
O
H H
H
H
OH
H
H
Tetronomycin
Streptomyces sp. NRRL 11266
5
7
8
6
3
9
10
11
O
12
13
14
15
16
17
18 19
20
21
22
23
33
34
O
1
2
O OH
30
O
29
24
27
OMe
26
O
H H
4
H
H
28
OH
H
25H
32
Tetronasin (1)
Streptomyces longisporoflavus
N O
O
H
H
Leporin B
Aspergillus flavus
NH
OH
H
HO
O
O
O
OO
OH
NH2
O
H
N
NH
O
HO
Pyrroindomycins
Streptomcyes rugosporus
R
R = H: Pyrroindomycin A
R = Cl: Pyrroindomycin B
OH
31
O HO
O
O OH
O
OMe
OH
HO
O
O OH
O
OMe
O
O
O
O OH
O
OMe
O
H H
H
H
OHOH
H
H
H
H H
H
H
H
25
23
21
19
17
151311975
31ACP
Proposed PKS-bound intermediate (2)
HO
MeO
H
H
OOHOO
7x malonyl-CoA
6x (2S)-methylmalonyl-CoA
S-adenosylmethionine
O2
TsnA1-A5 
TsnC, TsnB, TsnD
 formation of tetronate
ring and release from PKS
Tsn11Tsn15
Tetronasin (1) 4 3
OH
H
1
3
5
7
9
11 13
15
17
19
21
23
25
1
3
5
7 9
11
13
15
17
19
21
23
25
30
30
30
Figure 1. [4+2] cyclases in polyether tetronate biosynthesis. a, Structures of pyrroindomycin and leporin B, two polyketide natural products that 
require a [4+2] cyclase in their biosynthesis to create the rings highlighted in red. b, Structures of the polyether tetronate antibiotics tetronasin (1) and 
tetronomycin. c, Proposed role of the [4+2] cyclase homologues Tsn11 and Tsn15 in tetronasin biosynthesis.  
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Figure 2. Functional characterisation of the Diels-Alderase homologues Tsn11 and Tsn15 in tetronasin biosynthesis. a, The 
biosynthetic gene clusters of tetronomycin (tmn) and tetronasin (tsn) encode a VstJ-like (red) and PyrE3-like (yellow) [4+2] cyclase 
characteristic of spirotetronate and spirotetramate biosynthesis pathways including abyssomicin (aby), chlorothricin (chl), veripelostatin 
(vst), and pyrroindomycin (pyr). Only partial biosynthetic gene clusters are displayed and individual genes are not shown to scale. b, 
HPLC-MS analysis of the production of tetronasin 1 (m/z = 625) and intermediate 3 (m/z = 625) from wildtype S. longisporoflavus, S. 
longisporoflavus ∆tsn11, ∆tsn15, and ∆tsn11 ∆tsn15, gene deletion mutants, and genetically complemented S. longisporoflavus deletion 
mutants. Data are representative of three independent experiments. c, HPLC analysis of the in vitro conversion of intermediate 3 into 
tetronasin 1 using purified Tsn11 and Tsn15. Data are representative of three independent experiments. 
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Figure 3. Crystal structure of Tsn15. The crystal structure of Tsn15 was solved to 1.8 Å resolution using SAD phasing. a, Ribbon and surface 
representation of the homodimeric Tsn15. b. The active-site cavity within the β-barrel of Tsn15. Right: surface charge representation contoured 
at ±5 kT/eV; blue/red.  
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Figure 4 – Structural homologues of Tsn15 and their respective reactions.  The Cα chain of Tsn15 was aligned with its structural homologues 
AbyU, PyrI4, AOC2, and PodA. Beside each structure is its rmsd value to Tsn15, amino acid identity (%) to Tsn15, and the reaction it catalyses.  
O
HO
HO
O
O
O
O OH
H
H
H
H H
OH
O
HO
O
O
O
O
OHO
H
H
H
H
HH
4 Tetronasin 1
Tsn15
O
O
O O
HO
O
O
O O
HO
AbyU
H
H
OH
NH
O
HO
HO
H
H
OH
NH
O
HO
HO PyrI4
OO
O
OH
O
OH
O
O
AOC2
N
N
N
H
H
N
O OH
PodA
OHO
HO
O
O
O
O O
H
H
H
H H
5 
+45° 
	5 
α1 
α2 α3 
β3 
β4 
α4 
5 β1 
β6 
β7 
β2 
β8 
β5 
d 
β1 
α4 
β2 
β3 
β4 
β5 
β8 
β7 β6 
S142 
W190 
Q164 
5 
H2O H2O 
H2O 
c 
a b 
Chain A Chain A 
Fig. 5. Structure of Tsn15 and a Tsn15-substrate complex.  
a,  Fo-Fc of 5 (contoured to 2.0 σ ) and its chemical structure. b, Tsn15 in complex with intermediate 5. The Fo-F c map of 5 could be clearly assigned in the 
β-barrel cavity of Tsn15 chain A. Contouring to 2.0 σ. c, The detailed binding interactions between intermediate 5 and the internal β-barrel residues of 
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Fig. 6. Proposed mechanism for formation of the cyclohexane and tetrahydropyran rings of tetronasin. Tsn11 catalyses an inverse-
electron-demand hetero-Diels-Alder reaction to form an oxadecalin intermediate. The oxadecalin is hydrated to form the cyclic hemiacetal 
4 which was purified from the Tsn11 + 3 assay and structurally characterised. Tsn15 then catalyses dehydration of 4 to form 5 (which 
crystallised in the active site of Tsn15), followed by a pericyclic rearrangement to form the tetrahydropyran ring and fragment the 
oxadecalin, producing tetronasin 1.  
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